"Chemotherapy, Adjuvant" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drug therapy given to augment or stimulate some other form of treatment such as surgery or radiation therapy. Adjuvant chemotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.
| Descriptor ID |
D017024
|
| MeSH Number(s) |
E02.186.170 E02.319.170
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Chemotherapy, Adjuvant".
Below are MeSH descriptors whose meaning is more specific than "Chemotherapy, Adjuvant".
This graph shows the total number of publications written about "Chemotherapy, Adjuvant" by people in this website by year, and whether "Chemotherapy, Adjuvant" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 5 | 5 |
| 1996 | 0 | 6 | 6 |
| 1997 | 0 | 5 | 5 |
| 1998 | 0 | 6 | 6 |
| 1999 | 0 | 2 | 2 |
| 2000 | 0 | 2 | 2 |
| 2001 | 0 | 4 | 4 |
| 2002 | 0 | 7 | 7 |
| 2003 | 1 | 9 | 10 |
| 2004 | 2 | 3 | 5 |
| 2005 | 0 | 11 | 11 |
| 2006 | 1 | 10 | 11 |
| 2007 | 1 | 9 | 10 |
| 2008 | 2 | 8 | 10 |
| 2009 | 0 | 11 | 11 |
| 2010 | 0 | 13 | 13 |
| 2011 | 0 | 8 | 8 |
| 2012 | 1 | 11 | 12 |
| 2013 | 0 | 9 | 9 |
| 2014 | 0 | 8 | 8 |
| 2015 | 1 | 16 | 17 |
| 2016 | 1 | 7 | 8 |
| 2017 | 3 | 13 | 16 |
| 2018 | 1 | 13 | 14 |
| 2019 | 0 | 19 | 19 |
| 2020 | 0 | 6 | 6 |
| 2021 | 0 | 7 | 7 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 5 | 5 |
| 2024 | 0 | 7 | 7 |
| 2025 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Chemotherapy, Adjuvant" by people in Profiles.
-
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Long-term follow-up, crossover, and rechallenge with pembrolizumab in the phase III KEYNOTE-716 study. Eur J Cancer. 2025 May 02; 220:115381.
-
Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma in the randomized phase 3 CheckMate 76?K trial. Eur J Cancer. 2025 May 02; 220:115371.
-
Adjuvant Dose-Dense Chemotherapy in Hormone Receptor-Positive Breast Cancer. J Clin Oncol. 2025 Apr; 43(10):1229-1239.
-
Combining Biology-based and MRI Data-driven Modeling to Predict Response to Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer. Radiol Artif Intell. 2025 Jan; 7(1):e240124.
-
Accuracy of pre-operative tumor size assessment compared to final pathology and frequency of adjuvant treatment in patients with FIGO 2018 stage IB2 cervical cancer. Int J Gynecol Cancer. 2024 12 02; 34(12):1861-1866.
-
Real-world neoadjuvant and adjuvant Trastuzumab-containing regimen patterns and their association with survival among patients with operable HER2-positive breast cancer from 2007 to 2021. Breast Cancer Res Treat. 2025 Feb; 210(1):191-203.
-
Nodal Burden and Oncologic Outcomes in Patients With Residual Isolated Tumor Cells After Neoadjuvant Chemotherapy (ypN0i+): The OPBC-05/ICARO Study. J Clin Oncol. 2025 Mar; 43(7):810-820.
-
Laparoscopic Cytoreduction After Neoadjuvant Chemotherapy in High-Grade Epithelial Ovarian Cancer: A LANCE Randomized Clinical Trial. JAMA Netw Open. 2024 Nov 04; 7(11):e2446325.
-
Heterogeneity of Residual Disease After Neoadjuvant Systemic Therapy in Breast Cancer: A Review. JAMA Oncol. 2024 Nov 01; 10(11):1578-1584.
-
Significance of Residual Nodal Disease in Clinically Node-Negative Breast Cancer After Neoadjuvant Chemotherapy. Ann Surg Oncol. 2025 Feb; 32(2):922-930.